US Patent 7485700 Interferon-like protein ZCYTO21
Patent 7485700 was granted and assigned to ZymoGenetics on February, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+344 characters)
Article
Patent abstract
The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07485700 Interferon-like protein ZCYTO21 US Patent 7485700 Interferon-like protein ZCYTO21
Infobox
Patent Number
0748570000
Patent Number
748570000
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
074857000
Date of Patent
February 3, 2009
0Patent Application Number
115480560
Date Filed
October 10, 2006
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
074857000
Date of Patent
February 3, 2009
0Patent Application Number
115480560
Date Filed
October 10, 2006
0Official Website
Patent Primary Examiner
Edits on 14 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 1 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07485700 Interferon-like protein ZCYTO21
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07485700
Date of patent
February 3, 2009
Patent application number
11548056
Date Filed
October 10, 2006
Patent primary examiner
Find more entities like US Patent 7485700 Interferon-like protein ZCYTO21
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.